

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and Ascentage Pharma Group Corporation, Ltd.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed research agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Professor Shaomeng Wang is an employee of the University of Michigan (“University”) and a partial owner of Ascentage Pharma Group Corporation, Ltd. (“Ascentage”). The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Shaomeng Wang, PhD, a Professor in the Department of Internal Medicine – Hematology/Oncology, is a partial owner of a for-profit company called Ascentage (the “Company”). The Company wishes to fund a project entitled “A Multi-Center, Phase I/II Study of Combination Treatment of APG-1252 with Paclitaxel in Patients with Relapsed/Refractory Small Cell Lung Cancer” (ORSP #20-PAF02618) in the department of Internal Medicine – Hematology/Oncology under the direction of Dr. Angel Qin. The purpose of this project is to perform a multi-center, open-label phase I/II study of combination treatment with APG1252 plus paclitaxel in patients with relapsed/refractory small cell lung cancer (SCLC).

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed \$637,265. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreement will support an effort by Dr. Qin to use her expertise, as well as other University resources, to perform a multi-center, open-label phase I/II study of combination treatment with APG1252 plus paclitaxel in patients with relapsed/refractory SCLC.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with Ascentage Pharma Group Corporation, Ltd.

Respectfully submitted,



Rebecca Cunningham
Interim Vice President for Research

March 2020